IMMX - Immix Biopharma climbs on upcoming ASH readout
2023-11-06 15:35:37 ET
More on Immix Biopharma, Inc.
- Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum
- Immix gains FDA orphan drug status for CAR-T therapy
- Immix Biopharma director acquires $200K worth of shares
- Seeking Alpha’s Quant Rating on Immix Biopharma, Inc.
- Historical earnings data for Immix Biopharma, Inc.
For further details see:
Immix Biopharma climbs on upcoming ASH readout